CytoSorb® therapy for Liver and Kidney

CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based company involved in the R&D and commercialization of medical devices using its proprietary polymer adsorption technology. CytoSorbents is a leader in the treatment of life-threatening conditions in the ICU and cardiac surgery using blood purification.  Its flagship product, CytoSorb®, is distributed in more than 70 countries and has CE Mark approval in the EU for cytokine, bilirubin and myoglobin removal in numerous critical care applications and the removal of ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorbents has multiple active, clinical trials ongoing, including two pivotal randomized, controlled trials in the United States designed to support eventual FDA marketing approval for antithrombotic removal during cardiothoracic surgery using the DrugSorb™-ATR Antithrombotic Removal System.

U.S. Army Medical Research & Development Command

U.S. Department of Defense

Bridge Bank

CytoSorbents Corporation

Jazz Pharmaceuticals is a company focused on developing and commercializing innovative medical solutions.

Jazz Pharmaceuticals

Incyte is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel medicines.

Incyte

Toray Medical is a company known for its expertise in medical devices and healthcare solutions.

Toray Medical

ExThera Medical is a company focused on the development of innovative medical devices, specifically in the field of treating bloodstream infections.

ExThera Medical

OptiMedica Corp is a company known for its advancements in medical technology and solutions.

OptiMedica Corp

Cerus Corp is a company dedicated to developing and commercializing innovative blood transfusion products.

Cerus Corp

CytoSorbents Corporation is a U.S. medical device company focused on treating life-threatening conditions in the ICU and cardiac surgery using blood purification. The company's flagship product, CytoSorb®, is a blood purification cartridge approved in the European Union and distributed in 75 countries around the world to reduce cytokines and 'cytokine storm' that can cause massive inflammation, organ failure, and death in common critical illnesses.

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

Cytosorbents Corporation

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Feb 8, 2024 2:15 PM	9abdef93
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 8, 2024 2:15 PM	b07280b8
company summary	general
signals	general
crunchbase trigger	general	Nov 27, 2024 12:50 PM	8dade2b3
crunchbase profile	general
li profile	general	Feb 8, 2024 2:15 PM	71a47085
translate crunchbase fundingrounds	general
peers	general	Feb 8, 2024 2:15 PM	380e2732
news basic	general	Feb 8, 2024 2:15 PM	3f4e6be8
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:CYTOSORBENTS

CytoSorbents Corporation

Last Close

0.89

22/11 21:00

Market Cap

53.76M

Beta: -

Volume Today

76.86K

Avg: -